A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MICROSATELLITE INSTABILITY [MSI] AND/OR DEFICIENT MISMATCH REPAIR [DMMR] (NCT06004245)
BP44474
This trial is Currently recruiting
Registration number NCT06004245
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Malaka Ameratunga
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.